Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (cdc) | 0.10 |
| chemistry Open Targets | compounds already reach it: belatacept, abatacept, galiximab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 9,650 | 0.76 |
| pathways Reactome | 8 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 10981
Sealed predictions
- CD80 in dopamine neurons, braak-0.16 (p 0.685) → -0.05 (p 0.893)receipt 10989
Swarm cases
receipt 10989: CD80 in dopamine neurons, braak
- power
- full sample -0.03 (p 0.908, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.07 (p 0.781, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.434, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.08, sign flips 4; without severely affected donors -0.03 (p 0.908, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD80 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts